Why Analysts Still Have It Wrong With Arena [View article]
Rogaine was a greasy difficult to apply yucky application and it only worked for a small fraction of the people who used it. Twenty-three percent of the people who take Lorcasern will lose 10 percent or more of their body weight. Not exactly an apples to apples comparison.
A huge number of people bought options (calls and puts), currently well over 45 million shares. I think that the institutions holding those instruments have the ability to control the price per share (PPS) and will do so until they have escaped most of their risk. That is why the share price has stalled, the hedge funds are on the hook for $$$ if they can't escape and I have seen them do it before. But, the clock is ticking and they won't have too long to play their tricks.
Also Esai agreed (contractual obligation) to pay Arena $70 million upon FDA approval. This GAIN will probably be in Q3. In Q3 sales will be well under way. Consequently, real drug sales (profit) will show up almost immediately and profit is what large funds look at.
Also, Arena's production facility is in Switzerland has already bottled and shipped product to the USA, so there will be no production delay.
Let me just say that I am sleeping like a baby these days.
If Arena's Lorcaserin Is Approved, Buy Vivus [View article]
I think the fact that Qnexa will not be prescribed to women of child-bearing age based on proven causality of birth defects will also be a major factor to benefit Arena.
Arena Pharmaceuticals' Jump On Cramer's Favor May Be Premature [View article]
What the author seems to have overlooked is that Lorcaserin provided a 10 percent (or greater) weight loss for 25% of the study participants. Also, Lorcaserin does not interfere with normal sleep habits which is not true of Qnexa, in addition to the direct correlation with birth defects that Qnexa has demonstrated. Lorcaserin will be the Doctor's choice in most cases.
Arena Pharmaceuticals' Jump On Cramer's Favor May Be Premature [View article]
The Author seems to have missed the fact that twenty-five percent of Lorcaserin's study participants lost 10 percent or more of their body weight. In addition, Lorcaserin does not interfere with normal sleep habit, unlike Qnexa which does. Finally, the fact that Qnexa has proven to cause cleft pallets in infants of mothers that take the drug, Doctors will see Lorcaserin as the drug of choice for most patients.
Arena Pharmaceuticals: FDA Approval Is Just The Beginning [View article]
REmember that women who may become preg. will be advised by their doctor not to take Vivus' Qnexa, there is strong evidence that Qnexa does cause birth defects.
Why Analysts Still Have It Wrong With Arena [View article]
Arena: Bears Have It All Wrong [View article]
Also Esai agreed (contractual obligation) to pay Arena $70 million upon FDA approval. This GAIN will probably be in Q3. In Q3 sales will be well under way. Consequently, real drug sales (profit) will show up almost immediately and profit is what large funds look at.
Also, Arena's production facility is in Switzerland has already bottled and shipped product to the USA, so there will be no production delay.
Let me just say that I am sleeping like a baby these days.
If Arena's Lorcaserin Is Approved, Buy Vivus [View article]
Arena: Bears Have It All Wrong [View article]
Arena Pharmaceuticals' Jump On Cramer's Favor May Be Premature [View article]
Arena Pharmaceuticals' Jump On Cramer's Favor May Be Premature [View article]
Arena Pharmaceuticals: FDA Approval Is Just The Beginning [View article]